ABIVAX: Status of shares and voting rights as of September 30, 2025

On October 15, 2025, ABIVAX, listed on Euronext Paris, announced key information regarding its share capital. As of September 30, 2025, the company held 77,830,067 shares. The total number of voting rights, both theoretical and exercisable, amounts to 89,189,666. These rights serve as a reference for threshold crossing calculations, in accordance with the AMF General Regulations.

ABIVAX, with a share capital of 778,289.18 euros and headquarters in Paris, is focused on clinical-stage biotechnologies, primarily the development of the drug candidate obefazimod (ABX464) in phase 3 for ulcerative colitis.